Stellaromics Secures $25 Million In Series A Funding To Advance 3D Spatial Multi-Omic Profiling

Nov 02, 2023•about 2 years ago

Amount Raised

$25 Million

NatickBiotechnology

Investors

Plaisance Capital Management

Description

Stellaromics, a leading provider of in situ spatial multi-omics technology, today announced that the company has raised $25 million in a Series A financing round. The Series A financing round included Plaisance Capital Management and a private family office based in Silicon Valley.

Company Information

Company

Stellaromics

Location

Natick, Massachusetts, United States

About

Founded in 2022 and headquartered in Boston, Stellaromics is revolutionizing biomedical research with its proprietary technology, unraveling complex 3D transcription and translation patterns within native biological tissue. At the forefront of their innovation is STARmap (Spatially-resolved Transcript Amplicon Readout mapping), their flagship product. STARmap empowers researchers to uncover gene expression patterns within intact tissue, facilitating the pinpointing of treatment targets and bolstering biomedical investigations. Stellaromics is currently in the advanced stages of developing its Plexa™ suite of products, meticulously crafted to empower researchers and clinicians in the creation of intricate cellular maps, thereby amplifying our comprehension of various diseases. For comprehensive details, we invite you to explore our website at stellaromics.com. Join us in shaping the future of biomedical research.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends